108 related articles for article (PubMed ID: 12668017)
21. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells.
Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M
Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979
[TBL] [Abstract][Full Text] [Related]
22. Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138.
Mousa SA; Mohamed S
J Cardiovasc Pharmacol; 2005 Feb; 45(2):109-13. PubMed ID: 15654258
[TBL] [Abstract][Full Text] [Related]
23. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
24. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Marugán JJ; Manthey C; Anaclerio B; Lafrance L; Lu T; Markotan T; Leonard KA; Crysler C; Eisennagel S; Dasgupta M; Tomczuk B
J Med Chem; 2005 Feb; 48(4):926-34. PubMed ID: 15715463
[TBL] [Abstract][Full Text] [Related]
26. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.
Cheng H; Xie Z; Jones WP; Wei XT; Liu Z; Wang D; Kulp SK; Wang J; Coss CC; Chen CS; Marcucci G; Garzon R; Covey JM; Phelps MA; Chan KK
AAPS J; 2016 May; 18(3):737-45. PubMed ID: 26943915
[TBL] [Abstract][Full Text] [Related]
28. [Design and activity determination of small molecular inhibitors of integrin alphavbeta3].
Ji Q; Zhou Y; Peng H; Huang N; Qi J; Xiong DS; Gao YD; Yang M; Yang CZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun; 29(3):347-52. PubMed ID: 17633460
[TBL] [Abstract][Full Text] [Related]
29. Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
Zhong M; Shen W; Barr KJ; Arbitrario JP; Arkin MR; Bui M; Chen T; Cunningham BC; Evanchik MJ; Hanan EJ; Hoch U; Huen K; Hyde J; Kumer JL; Lac T; Lawrence CE; Martell JR; Oslob JD; Paulvannan K; Prabhu S; Silverman JA; Wright J; Yu CH; Zhu J; Flanagan WM
Bioorg Med Chem Lett; 2010 Sep; 20(17):5269-73. PubMed ID: 20655213
[TBL] [Abstract][Full Text] [Related]
30. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor.
Kumar CC; Nie H; Rogers CP; Malkowski M; Maxwell E; Catino JJ; Armstrong L
J Pharmacol Exp Ther; 1997 Nov; 283(2):843-53. PubMed ID: 9353406
[TBL] [Abstract][Full Text] [Related]
31. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Miller WH; Alberts DP; Bhatnagar PK; Bondinell WE; Callahan JF; Calvo RR; Cousins RD; Erhard KF; Heerding DA; Keenan RM; Kwon C; Manley PJ; Newlander KA; Ross ST; Samanen JM; Uzinskas IN; Venslavsky JW; Yuan CC; Haltiwanger RC; Gowen M; Hwang SM; James IE; Lark MW; Rieman DJ; Stroup GB; Azzarano LM; Salyers KL; Smith BR; Ward KW; Johanson KO; Huffman WF
J Med Chem; 2000 Jan; 43(1):22-6. PubMed ID: 10633035
[No Abstract] [Full Text] [Related]
32. The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
Bell IM; Bednar RA; Corcoran HA; Fay JF; Gallicchio SN; Johnston VK; Hershey JC; Miller-Stein CM; Moore EL; Mosser SD; Roller SA; Salvatore CA; Theberge CR; Wong BK; Blair Zartman C; Kane SA; Williams TM; Graham SL; Vacca JP
Bioorg Med Chem Lett; 2009 Aug; 19(16):4740-2. PubMed ID: 19577468
[TBL] [Abstract][Full Text] [Related]
33. New secondary metabolites of phenylbutyrate in humans and rats.
Kasumov T; Brunengraber LL; Comte B; Puchowicz MA; Jobbins K; Thomas K; David F; Kinman R; Wehrli S; Dahms W; Kerr D; Nissim I; Brunengraber H
Drug Metab Dispos; 2004 Jan; 32(1):10-9. PubMed ID: 14709615
[TBL] [Abstract][Full Text] [Related]
34. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacophore model of integrin alphavbeta3 antagonists].
Cheng GY; Ni GH; Jiang FC
Yao Xue Xue Bao; 2009 Apr; 44(4):379-85. PubMed ID: 19545055
[TBL] [Abstract][Full Text] [Related]
36. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
[TBL] [Abstract][Full Text] [Related]
37. New potent and selective αvβ
Wu Z; Cheng X; Hong H; Zhao X; Zhou Z
Bioorg Med Chem Lett; 2017 May; 27(9):1911-1913. PubMed ID: 28351594
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
39. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
40. Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template.
Nguyen DN; Paone DV; Shaw AW; Burgey CS; Mosser SD; Johnston V; Salvatore CA; Leonard YM; Miller-Stein CM; Kane SA; Koblan KS; Vacca JP; Graham SL; Williams TM
Bioorg Med Chem Lett; 2008 Jan; 18(2):755-8. PubMed ID: 18039571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
